Advisory committee
FDA advisory committee meetings, agendas, and what their votes do and don't mean.
When a headline says an "FDA panel backs" something, what actually happened? FDA's advisory committees give the agency outside expert advice. For peptides, the one to know is the Pharmacy Compounding Advisory Committee (PCAC). Its vote is a recommendation, not a decision.
PCAC met July 23 and 24, 2026 on seven peptides. [V] AJMC reported that the committee recommended six of the seven, including 8-6 votes with one abstention on BPC-157, KPV and TB-500. FDA's meeting page showed no vote summary when we checked, so we treat those counts as secondary. [S] FDA's early announcement of its next meeting, before the end of February 2027, lists five substances: GHK-Cu, PEG-MGF, melanotan II, LL-37 and dihexa acetate. That page was current as of April 15, 2026. [V] After a meeting, FDA still has to act, usually through notice-and-comment rulemaking.
Evidence labels: [V] verified in a primary document, [S] secondary source. Reviewed October 25, 2026.
Posts in this topic
- FDA
- Advisory committee
- Policy
Where peptide regulation stands right now: a plain-English timeline
A plain-English timeline of peptide regulation as of October 25, 2026: what FDA documents show, what is only reported, and what is still pending.
- Compounding
- Advisory committee
- Wellness
GHK-Cu is in skincare and on FDA's compounding list. Here's what "except injectable" means
GHK-Cu, the copper peptide in skincare, is on FDA's Category 1 compounding list except for injectables, with an advisory meeting due by February 2027.
Common questions
Does an advisory committee vote change the rules?
No. A vote is a recommendation. FDA still decides, usually through notice-and-comment rulemaking. [V]
When is the next peptide meeting?
FDA's early announcement says it will host a meeting before the end of February 2027. We have not found a posted date. [V]
Key terms in plain English
- PCAC
- The Pharmacy Compounding Advisory Committee, which advises FDA on compounding questions. [V]
- Advisory vote
- A recommendation. FDA is not bound to follow it.
- Notice-and-comment rulemaking
- FDA publishes a proposal and takes public comments before finalizing a rule. [V]
Primary sources behind this page
- FDA, PCAC meeting page (retrieved Oct. 25, 2026)
- FDA, July 23-24, 2026 PCAC meeting (retrieved Oct. 25, 2026)
- AJMC, FDA panel backs 6 peptides for compounding (secondary) (July 31, 2026)